arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

TG THERAPEUTICS, INC.

TGTX
$49.55 ▼ -0.32 (-0.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
81 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

TG THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $7.2B
Dividend Yield
Revenue Growth 69.6%
Op. Margin 17.0%
ROIC 2.5%
FCF / Share $-0.12
Trailing P/E 353.9x
Price / Book 13.0x
FCF Yield
Debt / Equity 1.28
info Valuation on last close. End-of-day price, Aug 6, 2026.

81-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$204.92M
↑ +69.6%
Net Income Profit after all expenses
$19.78M
↑ +290.8%
Operating Margin Operating profit as % of sales
17.0%
↓ -35.2% 75th
FCF / Share Free cash flow per share
$-0.12
↑ +36.6%
Long-Term Debt Long-term obligations
$745.14M
↑ +203.3%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
64
Returns
98
Financial Health
66
Cash Quality
20

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 81 quarters